{"id":"W2922237910","doi":"10.1182/blood-2018-11-880526","title":"Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":136,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Cilag; Pharmacyclics; National Cancer Institute; H. Lundbeck A/S; Servier; Amgen; TG Therapeutics; Genentech; Celgene; Gilead Sciences; F. Hoffmann-La Roche","keywords":"Venetoclax; CHOP; Medicine; Internal medicine; Lymphoma; Radioimmunotherapy; Oncology; Cancer research; Immunology; Leukemia; Chronic lymphocytic leukemia; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002301511,0.0002134321,0.0004466314,0.00005137405,0.00004827976,0.00003462734,0.000159221,0.0001301519,0.0001633389],"category_scores_gemma":[0.0001950041,0.0001200007,0.0001360235,0.0001966612,0.00003455608,0.00004745098,0.00005811645,0.00008080967,0.0004539592],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004362506,"about_ca_system_score_gemma":0.0007586963,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003836807,"about_ca_topic_score_gemma":0.0004355691,"domain_scores_codex":[0.9984415,0.00006955789,0.0004302956,0.0004296996,0.0003187603,0.0003101724],"domain_scores_gemma":[0.9984525,0.000575938,0.0001175326,0.0007002418,0.00003356639,0.0001201843],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7112298,0.06925939,0.06290647,0.000148283,0.00348675,0.008948167,0.01205765,0.00009971583,0.004692775,0.0003102325,0.03256977,0.09429096],"study_design_scores_gemma":[0.9370598,0.00302186,0.04107529,0.0002479225,0.0004821142,0.00003933816,0.0001904361,0.000269927,0.005247995,0.0000403203,0.01212492,0.0002000692],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9929409,0.000495231,7.203509e-7,0.0007149611,0.0004821207,0.001730702,0.0001688266,0.00003724952,0.003429303],"genre_scores_gemma":[0.9972082,0.0001544221,0.0001551893,0.0005245089,0.0006312835,0.0001665684,0.0001593242,0.00002762765,0.0009729094],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.22583,"threshold_uncertainty_score":0.5834879,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0250096202725218,"score_gpt":0.2999874654202687,"score_spread":0.2749778451477469,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}